Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
Type:
Grant
Filed:
July 27, 2010
Date of Patent:
May 24, 2016
Assignee:
Genentech, Inc.
Inventors:
Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
Abstract: The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.
Type:
Grant
Filed:
January 31, 2013
Date of Patent:
May 24, 2016
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.
Type:
Grant
Filed:
May 30, 2008
Date of Patent:
April 26, 2016
Assignee:
GENMAB A/S
Inventors:
Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Paul Parren, Willem Karel Bleeker, Frank Beurskens, Patrick Van Berkel
Abstract: Provided is a novel therapeutic agent specific for a malignant tumor expressing MHC class II. The present invention provides an antibody recognizing a protein constituting MHC class II expressed on a malignant tumor, the antibody comprising at least one selected from heavy chain CDR1 (amino acid sequence represented by positions 49 to 54 of SEQ ID NO: 54), heavy chain CDR2 (amino acid sequence represented by positions 69 to 84 of SEQ ID NO: 54), heavy chain CDR3 (amino acid sequence represented by positions 117 to 128 of SEQ ID NO: 54), light chain CDR1 (amino acid sequence represented by positions 46 to 55 of SEQ ID NO: 56), light chain CDR2 (amino acid sequence represented by positions 71 to 77 of SEQ ID NO: 56), and light chain CDR3 (amino acid sequence represented by positions 100 to 108 of SEQ ID NO: 56).
Abstract: Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds high molecular weight melanoma associated antigen (HMW-MAA), also known as CSPG4; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.
Type:
Grant
Filed:
December 1, 2011
Date of Patent:
March 29, 2016
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Abstract: The present invention relates to the field of diagnostic tests and diagnostic tools. Specifically, contemplated is to a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer comprising contacting the sample with an antibody which specifically binds to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide under conditions which allow for binding of said antibody to the epitope and determining binding of the antibody to the epitope, whereby cancer is diagnosed. Further contemplated are antibodies which specifically bind to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide and a device or kit comprising such antibodies.
Abstract: Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (ALL) or a predisposition to ALL, uses and compositions are disclosed.
Type:
Grant
Filed:
August 18, 2015
Date of Patent:
March 29, 2016
Assignee:
The Ohio State University Research Foundation
Abstract: A method of inhibiting tumor angiogenesis in an individual, the method comprising administering to the individual an inhibitor of CLEC14A. The inhibitor may be an antibody, an siRNA molecule, an antisense molecule, or a ribozyme.
Type:
Grant
Filed:
September 3, 2010
Date of Patent:
February 9, 2016
Assignee:
Cancer Research Technology Limited
Inventors:
Roy Bicknell, Xiaodong Zhuang, Manuela Mura
Abstract: Disclosed herein are a monoclonal antibody that specifically binds to human CD 133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.
Type:
Grant
Filed:
December 10, 2010
Date of Patent:
February 2, 2016
Assignee:
Regents of the University of Minnesota
Inventors:
John R. Ohlfest, Karen Himmel Ohlfest, Jayanth Panyam, Suresh Kumar Swaminathan, Daniel A. Vallera
Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.
Type:
Grant
Filed:
December 13, 2013
Date of Patent:
January 19, 2016
Assignee:
UNIVERSITÄTSKLINIKUM FREIBURG
Inventors:
Ursula Elsässer-Beile, Philipp Wolf, Dorothee Gierschner, Patrick Bühler, Ulrich Wetterauer
Abstract: Cytotoxic variants of human ribonuclease 1 (RNase 1) identified through analysis of the interaction between RNase 1 and the human ribonuclease inhibitor (hRI) as defined by the three dimensional (3-D) atomic structure of the RNase1 hRI complex are disclosed. Also disclosed is the 3-D structure of the hRI.RNase 1 complex and methods for designing and using the RNase 1 variants.
Type:
Grant
Filed:
October 4, 2013
Date of Patent:
January 12, 2016
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Ronald T. Raines, George N. Phillips, Jr., R. Jeremy Johnson, Jason G. McCoy
Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
Type:
Grant
Filed:
August 13, 2012
Date of Patent:
December 22, 2015
Assignee:
Anthrogenesis Corporation
Inventors:
Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
Abstract: A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods.
Type:
Grant
Filed:
July 23, 2013
Date of Patent:
December 15, 2015
Assignee:
SAMSUNG ELECTRONICS CO., LTD.
Inventors:
Ji Min Lee, Kyung Ah Kim, Bo Gyou Kim, Young Mi Oh, Saet Byoul Lee, Yun Ju Jeong
Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
Type:
Grant
Filed:
January 8, 2010
Date of Patent:
December 15, 2015
Assignee:
Seattle Genetics, Inc.
Inventors:
Eric Sievers, Dana Kennedy, Nathan Ihle, Michael Sun
Abstract: A method of identifying a cell sample or subject suitable for treatment with an anti-c-Met antibody or antigen-binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining the presence of LRIG1 in a cell sample from the subject, as well as related methods and compositions.
Abstract: Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention/treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer.
Type:
Grant
Filed:
December 13, 2012
Date of Patent:
December 8, 2015
Assignee:
Ruprecht-Karls-Universität
Inventors:
Matthias Kloor, Miriam Reuschenbach, Magnus von Knebel-Doeberitz
Abstract: Methods and formulations for diagnosing oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.
Type:
Grant
Filed:
May 11, 2010
Date of Patent:
December 8, 2015
Assignee:
Berg LLC
Inventors:
Niven Rajin Narain, John Patrick McCook, Rangaprasad Sarangarajan
Abstract: The present invention is directed to methods for treating cancer in a subject, such as a cancer of the endocrine system. In some aspects, the method includes administering to the subject one or more of a polo-like kinase 1 inhibitor, a mouse double minute 2 inhibitor, and/or a mitotic catastrophe inducing compound. In other aspects, the method includes measuring an expression level of one or more markers, including caspase 8 and caspase 9, to assess the functionality of the caspase cascade in the subject.
Type:
Grant
Filed:
April 4, 2014
Date of Patent:
December 1, 2015
Assignee:
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
Inventors:
Kimberly J. Bussey, Michael J. Demeure, Aditi Bapat
Abstract: Disclosed is a use of the CUEDC2 protein in the preparation of diagnostic agents for prognostic determination of the endocrinology therapy for the breast cancer patients and for the diagnosis of tumor such as breast cancer and ovarian cancer. The diagnostic agent comprises an antibody against the CUEDC2 protein, wherein the antibody is a monoclonal or polyclonal antibody against the CUEDC2 protein. Provided is a kit or a composition for prognostic determination of endocrinology therapy for the breast cancer patients and for the diagnosis of tumors such as breast cancer and ovarian cancer. The kit or composition comprises an antibody against the CUEDC2 protein. Further disclosed is a use of the CUEDC2 gene or protein in preparation of drugs for treating tumors, that is, small molecular substances and specific antibodies that specifically inhibit the expression or activity of the CUEDC2 gene\protein are used as a therapeutic agent to restore the sensitivity of drug-resistant tumors to drug treatment.
Type:
Grant
Filed:
October 28, 2011
Date of Patent:
December 1, 2015
Assignee:
Biomedical Analysis Center of Academy of Military Medical Sciences
Inventors:
Xuemin Zhang, Tao Zhou, Xin Pan, Huiyan Li, Ailing Li